# Pharmacokinetics, Safety and Immunogenicity of RPH-104 at a New Dosage and Different Doses Via Single Subcutaneous and Intravenous Administration in Healthy Volunteers

> **NCT07206043** · PHASE1 · COMPLETED · sponsor: **R-Pharm International, LLC** · enrollment: 130 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** RPH-104 80 mg
- **BIOLOGICAL:** RPH-104 160 mg
- **BIOLOGICAL:** RPH-104 320 mg
- **BIOLOGICAL:** RPH-104 320 mg
- **BIOLOGICAL:** RPH-104 80 mg
- **BIOLOGICAL:** RPH-104 80 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07206043
- **Lead sponsor:** R-Pharm International, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-12-03
- **Primary completion:** 2025-02-27
- **Final completion:** 2025-07-25
- **Target enrollment:** 130 (ACTUAL)
- **Last updated:** 2025-10-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07206043

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07206043, "Pharmacokinetics, Safety and Immunogenicity of RPH-104 at a New Dosage and Different Doses Via Single Subcutaneous and Intravenous Administration in Healthy Volunteers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07206043. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*